Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SLC19A2 | O60779 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1767822 | 0.88 | TLR8 (0.38) | NOS2NPSR1ALOX15MAPTCYP2C9 | |
| SCHEMBL12597094 | 0.86 | KCNH2 (0.41) | NPSR1KDM4ETDP1TLR8 | |
| SCHEMBL27634918 | 0.84 | KCNH2 (0.44) | KDM4ELMNATDP1ALDH1A1TLR8 | |
| SCHEMBL11310160 | 0.84 | KCNH2 (0.44) | KDM4ELMNATDP1ALDH1A1TLR8 | |
| SCHEMBL1422106 | 0.82 | — | — | |
| SCHEMBL28898640 | 0.81 | NPSR1 (0.38) | NOS2GRM5NPSR1ALOX15MAPT | |
| Hydrochloric Acid SCHEMBL3890783 | 0.79 | MAPT (0.41) | NOS2NPSR1ALOX15MAPTCYP2C9 | |
| SCHEMBL12832394 | 0.79 | ALOX15 (0.36) | GRM5NPSR1ALOX15MAPTCYP2C9 | |
| SCHEMBL27592765 | 0.78 | KDM4E (0.42) | NOS2MAPTKDM4ELMNAALDH1A1 | |
| SCHEMBL8666663 | 0.78 | ALOX15 (0.38) | NPSR1ALOX15MAPTCYP2C9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021155317-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2018128720-A1 | URACIL CONTAINING COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-07-12 | — | — | WO | disclosed |
| US-20160194303-A1 | HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2016-07-07 | — | — | US | disclosed |
| US-20130012492-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2013-01-10 | — | — | US | disclosed |
| EP-1956022-A1 | COMPOUND FOR ORGANIC ELECTROLUMINESCENT ELEMENT AND ORGANIC ELECTROLUMINESCENT ELEMENT | Nippon Steel Chemical Co., Ltd. (JP) | 2008-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194303-A1 | HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | ICOS, NFATC1, CD74 | NOS2 1286/4885GRM5 3114/4885NPSR1 2314/4885 |
| US-20130012492-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNJ4 | NOS2 2511/4885GRM5 491/4885NPSR1 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.